Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares for the month of April 2025. The filing details a specific share repurchase executed on March 31, 2025, pursuant to a non-discretionary agreement with Citigroup Global Markets Limited entered into on February 24, 2025.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities regarding share buybacks. No revenue, profit, cash flow, or debt metrics are disclosed in this document.
- Shares Purchased (March 31, 2025): 836,600 ordinary shares.
- Price Range (GBp): Lowest 1,453.50p; Highest 1,482.50p.
- Volume-Weighted Average Price (GBp): 1,465.18p.
- Cumulative Buyback (Since Feb 24, 2025): 18,236,887 ordinary shares.
- Total Treasury Shares Held: 187,307,190 ordinary shares.
- Ordinary Shares in Issue (Excluding Treasury): 4,127,914,542.
- Total Voting Rights: 4,127,914,542.
Material Changes
The filing reports a reduction in the number of shares outstanding due to the acquisition of treasury stock. The Company holds 187,307,190 shares in treasury following the March 31 transaction. The filing does not provide comparative financial data against prior periods as it is a transactional report rather than a financial statement.
Guidance, Outlook, and Risks
The Company states that the purchased shares will be held as Treasury shares. The transaction was executed under a non-discretionary agreement. The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the GSK 2024 Annual Report on Form 20-F (pages 277 to 285). No specific financial guidance or outlook is provided in this document.
Investor Verification Checklist
- Verify the total number of voting rights (4,127,914,542) for disclosure threshold calculations under FCA rules.
- Confirm the cumulative volume of shares repurchased since the February 24, 2025 agreement (18,236,887 shares).
- Review the GSK 2024 Annual Report on Form 20-F for detailed risk factors referenced in the cautionary statement.
- Note that the filing does not contain operational or financial performance data (revenue, earnings, cash flow).